SCHEMBL282282

SCHEMBL282282

O=S(=O)(Cl)c1cc(F)c(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 14/20 0.41
CA2 P00918 14/20 0.41
CA12 O43570 2/20 0.41
CA7 P43166 2/20 0.41
CA13 Q8N1Q1 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
CA9 Q16790 7/20 0.38
CA4 P22748 3/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
PTGS2 P35354 1/20 0.34
CA3 P07451 1/20 0.33
KMT2A Q03164 1/20 0.31
GRM4 Q14833 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16177831 0.84 CA1 (0.46) CA1CA2CA12CA7CA13
SCHEMBL30876263 0.84 CA1 (0.46) CA1CA2CA12CA7CA13
SCHEMBL28018499 0.81 CES2 (0.39) CA1CA2CA12CA7CA13
SCHEMBL7919248 0.80 ALDH1A1 (0.37) CA1CA2CA12CA7TDP1
SCHEMBL1541882 0.80 CA1 (0.41) CA1CA2CA12CA7TDP1
SCHEMBL22919992 0.80 EPAS1 (0.35) CA1CA2CA12CA7CA13
SCHEMBL2536209 0.80 CYP3A4 (0.39) CA1CA2CA12CA7CA13
SCHEMBL25252706 0.78 VCAM1 (0.51) CA1CA2CA12TDP1ALDH1A1
SCHEMBL30489366 0.78 VCAM1 (0.51) CA1CA2CA12TDP1ALDH1A1
SCHEMBL5151223 0.78 CA1 (0.44) CA1CA2CA12CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 CN claimed
CN-119528810-B Quinoline compound and application thereof 山东第一医科大学(山东省医学科学院) 2025-04-29 CN disclosed
CN-119528810-A Quinoline compound and application thereof 山东第一医科大学(山东省医学科学院) 2025-02-28 CN disclosed
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2025-02-13 US disclosed
CN-119390708-A Novel curcumenol derivative and synthetic method and application thereof 天津中医药大学 2025-02-07 CN disclosed
EP-4499609-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2025-02-05 EP disclosed
CN-119301096-A Inhibitors of MYST family lysine acetyltransferase 伊索斯泰里克斯公司 2025-01-10 CN disclosed
CN-119264303-A Pendant group functionalized fluorine-containing polymer, preparation method of fluorine-containing polymer, ion exchange membrane and application 佛山绿动氢能科技有限公司 2025-01-07 CN disclosed
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases Isosterix, Inc. (US) 2025-01-07 US disclosed
CN-119264026-A Method for synthesizing cyclic sulfonamide and sulfonyl olefin by mechanical light excitation 西北大学 2025-01-07 CN disclosed
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma SYMPHONY EVOLUTION, INC. 2006-09-07 US disclosed
EP-1656361-A1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
US-20050227973-A1 Human adam-10 inhibitors EXELIXIS, INC. 2005-10-13 US disclosed
US-20050209241-A1 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. 2005-09-22 US disclosed
EP-1511488-A2 HUMAN ADAM-10 INHIBITORS Exelixis, Inc. (US) 2005-03-09 EP disclosed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US disclosed
WO-2005014563-A1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-17 WO disclosed
EP-1461313-A1 HUMAN ADAM-10 INHIBITORS Exelixis, Inc. (US) 2004-09-29 EP disclosed
WO-2003106381-A2 HUMAN ADAM-10 INHIBITORS EXELIXIS, INC. (US) 2003-12-24 WO disclosed
WO-2003051825-A1 HUMAN ADAM-10 INHIBITORS EXELIXIS, INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209241-A1 Benzoyl-piperazine derivatives SLC1A2, SLC18A2, SLC6A7 CA1 4221/4885CA2 3258/4885CA12 4755/4885
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A CA1 3845/4885CA2 4141/4885CA12 4272/4885
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases KAT6A, KAT6B, KAT2A CA1 3845/4885CA2 4141/4885CA12 4272/4885
US-20050227973-A1 Human adam-10 inhibitors ADAM10, ADAM12, ADAM9 CA1 461/4885CA2 1016/4885CA12 497/4885
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CA1 2141/4885CA2 1262/4885CA12 1392/4885
US-20060199820-A1 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma ADAM10, MMP20, MMP10 CA1 192/4885CA2 1122/4885CA12 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.